Lecture
Drug Development and Regulations: Europe
Description
This lecture covers the drug development process in Europe, from discovery to marketing authorization. It explains the phases of clinical trials, the European regulatory framework, the new Clinical Trials Regulation, and the Clinical Trials Information System. The transition from the Clinical Trial Directive to the Clinical Trials Regulation is detailed, along with the life cycle of a clinical trial application. The importance of transparency in clinical trials, the Marketing Authorization Application dossier, and the different Marketing Authorization Procedures and types in Europe are also discussed.
Official source
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Ontological neighbourhood
Related lectures (33)
Preclinical Animal Models: Selection & Rationale
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Drug Development and Ethical Principles
Explores the historical aspects of drug development, regulatory agencies, and ethical principles in pharmacology, emphasizing the importance of informed consent and human subject protection.
Peptide Therapeutics
Explores the development and advantages of peptide therapeutics, including conversion into peptidomimetics and solid phase peptide synthesis.
Causality and Clinical Studies
Explores causality, clinical studies, new drug evaluation, confounding factors, and data analysis methods.
Quality Assurance in Drug Development
Explores the regulatory environment for quality compliance in drug development and emphasizes the importance of preventative measures and documentation.